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Anticoagulation at JFMA
• More team based anticoagulation management
• Nurse coordinator for anticoagulation at JFMA will be Catherine Disandro (Katie)
• Anticoagulation patients will be managed by a combination of the PCP and the
nurse coordinator so each PCP will be receiving a list of their patients on warfarin
soon and eventually those patients on DOACs
• The majority of the time the patients will see their PCP for anticoagulation
management
• There will also be a nurse run with resident and pharmacy resident support
anticoagulation clinic on Thursday afternoons for patients who need more
supervision or when the PCP is unavailable.
• The anticoagulation nurse and medical assistant (Shakia Miller) will review home
draw and home INR machine results and will contact the patients.
• Warfarin doses will be adjusted by the nurse per protocol. The PCP will be
contacted as needed.
• The anticoagulation nurse and medical assistant will also keep track of
anticoagulation patients who do not keep their appointments to have their INR
done.

Objectives
•Warfarin Management
•Anticoagulation Module in Epic
•Brief summary of Direct Oral Anticoagulants
(DOACs)
•Brief Perioperative Anticoagulation Tips

US emergency department visits for oral anticoagulant related bleeding, by year, 2011–2017.
Estimates from the National Electronic Injury Surveillance System–Cooperative Adverse Drug
Event Surveillance project, CDC. Excludes n = 40 cases implicating both warfarin and a DOAC
(2011, n = 2 cases; 2013, n = 3 cases; 2014, n = 7 cases; 2015, n = 8 cases; 2016, n = 9 cases;
2017, n = 11 cases). DOAC, direct-acting oral anticoagulant.

Geller et al

Indications for Oral Anticoagulation
• Treatment of existing thrombosis

Acute venous thromboembolism (VTE)

• Primary prevention of thrombosis

Patients with atrial fibrillation (AFib) with an increased risk of stroke
Patients with mechanical heart valves
Extended VTE prophylaxis following major orthopedic surgeries

• Secondary prevention of thrombosis

Patients with a history of VTE for which benefits of treatment outweigh risks
Patients with Afib and a history of cardioembolic stroke

• Reduction in the risk of death, recurrent myocardial infarction, and thromboembolic
events such as stroke or systemic embolization after myocardial infarction
• Reduction in risk of major cardiovascular events in patients with coronary artery
disease (CAD) or peripheral artery disease (PAD)
2020 U.S. Food & Drug Administration

Direct Acting Oral
Anticoagulants
(DOACs) and Vitamin K
Antagonists
• Direct Thrombin Inhibitor
• Dabigatran
• Factor Xa Inhibitors
• Apixaban
• Edoxaban
• Rivaroxaban
• Factors II, VII, IX, and X
Inhibitors
• Vitamin K antagonists
–Warfarin
•

John N. Makaryus,Jonathan L. Halperin&Joe F. Lau, Oral
anticoagulants in the management of venous
thromboembolism, Nature Reviews CardiologyVolume 10

2020 U.S. Food & Drug Administration

Warfarin
Ø Interferes

with Vitamin K dependent clotting
factors (II, VII, IX, X)
Ø Antithrombotic effect measured by PT
Ø Interlab variability in thromboplastins – INR
Ø Earliest INR changes 24-36 hours after dose
Ø Antithrombotic effect is not present until ~
day 5

Genetic Testing for
Warfarin Dosing (Not recommended)
Ø

2 Tests available
1. Sensitivity to warfarin - VKORC1
(vitamin K epoxide reductase) test.
VKORC1 is the gene that codes for
enzyme at site where warfarin exerts
effect
2. Rate of metabolizing warfarin –
CYP2C9 test. CYP2C9 is the liver
enzyme which breaks down S-warfarin
(more active half of warfarin).
Bussey HI et al. www.clotcare.com/clotcare/warfaringentictesting.aspx, July 2007

Vitamin K Epoxide Reductase VKORC1
Ø Sensitive

(AA genotype) less warfarin
more common in Asians
Ø Resistant (GG genotype) more warfarin
more common in blacks
Ø In between (AG genotype) average
warfarin

Bussey HI et al. www.clotcare.com/clotcare/warfaringentictesting.aspx, July 2007

CYP2C9 Variant
Ø Metabolize

warfarin more slowly
Ø Accumulate warfarin in blood over a longer period of time
Ø Take longer to reach a stable INR – need more warfarin
initially then may need to cut back on dose
Ø Slow metabolizers – lower dose warfarin maintenance

Bussey HI et al. www.clotcare.com/clotcare/warfaringentictesting.aspx, July 2007

Warfarin Dosing Regimen
Ø Highest

in CYP2C9 homozygous for wild type compare to

variants
Ø GG genotype>AG genotype>AA genotype
Ø Mean daily dose warfarin dose fell 0.5-0.7mg/decade
between 20-90 years old
Ø Age, height, and CYP2C9 significantly contributed to Swarfarin and total warfarin clearance
Ø Age and body size to R-warfarin clearance
Sconce EA et al. Blood 2005;106:2329-2333

Warfarin Medication Interactions
Ø Inhibition

of Metabolism:
Metronidazole, trimethoprim/sulfa
Ø Potentiation:
Amiodarone long half-life 60 days
Ø Hepatic metabolism induced:
Barbiturates, carbamazepine, rifampin
Ø Increase metabolism of coagulation factors:
thyroxine
Ø Inhibition of platelet activity:
NSAIDS

Disease State Interactions
Ø Hepatic

congestion (CHF, liver disease,
cancer) – reduce warfarin metabolism
Ø Hyperthyroidism – Increase metabolism of
coagulation facts
Ø Diarrhea – loss of vitamin K foods
Ø Anorexia – decreased intake vitamin K foods

Food Interactions
Ø Foods with high vitamin K content –
Ø Consistent amounts rather than avoiding

completely

Enteral feeds with high vitamin K content
Avocados (large amounts), broccoli, brussel sprouts, cabbage,
collard greens, raw endive, kale, bib leaf and red leaf lettuce,
mustard greens, parsley, spinach, raw swiss chard, raw turnip
greens, watercress
Green tea

Mayonnaise

Drugs That Increase the Potency of Warfarin
Acetaminophen
Alcohol (if concomitant liver
disease)
Amiodarone (Cordarone)
Anabolic steroids
Cimetidine (Tagamet)
Ciprofloxacin (Cipro)
Disulfiram (Antabuse)
Erythromycin
Fluconazole (Diflucan)
Influenza vaccine
Isoniazid (Nydrazid)
Itraconazole (Sporanox)
Lovastatin (Mevacor)
Moxifloxacin (Avalox)

Metronidazole
Miconazole (Monistat)
Nonsteroidal anti-inflammatory drugs
Norfloxacin (Noroxin)
Ofloxacin (Floxin)
Omeprazole (Prilosec)
Phenytoin (Dilantin)
Propafenone (Rythmol)
Propranolol (Inderal)
Propoxyphene (Darvon)
Quinidine
Salicylates
Tamoxifen (Nolvadex)
Tetracycline
Thyroxine
Trimethoprim/sulfamethoxazole (Bactrim,
Septra)

Herbal Products That Increase the Potency of
Warfarin
Danshen
Devil's claw
Dong quai
Garlic
Ginkgo
Papain
Vitamin E

Drugs and Herbal Products That Decrease the
Potency of Warfarin
Drugs
Herbal products
Azathioprine (Imuran)
Carbamazepine (Tegretol)
Barbiturates
Cholestyramine (Questran)
Cyclosporine (Sandimmune)
Dicloxacillin (Dynapen)
Griseofulvin (Grisactin)
Nafcillin
Rifampin (Rifadin)
Sucralfate (Carafate)
Trazodone (Desyrel)

Coenzyme Q10
Ginseng
St. John's wort

Warfarin Therapy
INDICATION
GOAL DURATION
Ø Prevention of VTE
Orthopedic surgery
Elective THR 2-3
Elective TKR 2-3
Hip fracture surgery 2-3
Ø

VTE and PE
DVT or PE

2-3

25-35 days
At least 10 days
28-35 days
1st episode reversible factors: 3
mos.
1st episode idiopathic: 6-12 mos.
Cancer pts: LMWH for 3-6 mos.
then warfarin indefinitely
2 episodes of objectively
documented events: indefinite

Warfarin Therapy
INDICATION
Ø Atrial fibrillation

GOAL

High risk of stroke
Persistent or PAF
Atrial flutter
Elective
cardioversion

DURATION

2-3 Indefinite
2-3 Indefinite
2-3 Indefinite
2-3 3 weeks before; 4
weeks after

Warfarin Therapy

INDICATION
GOAL
Ø Valvular Heart Disease
Rheumatic mitral valve
disease + a fib or
embolism
Mitral valvuloplasty

DURATION

2-3

Long-term

2-3

3 weeks before;4 weeks
after

Mechanical prosthetic valves
Mitral valve
2.5-3.5
Aortic valve:
St. Jude bileaflet
2-3
Carbomedics bileaflet
2-3
Medtronic Hall tilting disc 2-3
Ball/cage
2.5-3.5+ASA
Mechanical valve
2.5-3.5
+ risk factor
Bioprosthetic valve
2-3

Long-term
Long-term
Long-term
Long-term
Long-term
Long-term
3 months

Initiating Warfarin
Therapy
5 mg Warfarin
Initiation Nomogram

Ebell MH. Am Fam Physician 2005;71:1979-82

Day

INR

Dose (mg)

1

-

5.0

2

-

5.0

3

< 1.5
1.5 to 1.9
2.0 to 3.0
> 3.0

10.0
5.0
2.5
0.0

4

< 1.5
1.5 to 1.9
2.0 to 3.0
> 3.0

10.0
7.5
5.0
0.0

5

< 2.0
2.0 to 3.0
> 3.0

10.0
5.0
0.0

6

< 1.5
1.5 to 1.9
2.0 to 3.0
> 3.0

12.5
10.0
7.5
0.0

.

Treatment of DVT and PE
Ø
Ø

Ø

Ø
Ø

Initiate warfarin and LMWH (or UFH) on day 1
Use 5 mg nomogram to initiate warfarin therapy
and monitor INR per nomogram protocol to
target of 2 – 3
Stop LMWH or UFH after no less than 5 days
and when INR stable at ≥ 2 or more for 2
days
Use elastic compression stockings 30-40mm at
ankle to prevent post thrombotic syndrome
Ambulate as tolerated

Warfarin Maintenance
Ø Monitor

initially twice weekly or more, weekly,
every 2 weeks, every 3 weeks, but usually at least
every 4 weeks
Ø Increase spacing depending on how many weeks
the INR has been stable
Ø CHEST Guidelines suggest longer intervals of up
to 12 weeks may be considered in patients with
consistently stable INRs

Adjusting Warfarin Dosing
ØOut

of range INR’s – attempt to find
cause
ØAdjust dose 5 to 20% of total weekly dose
up or down
ØDo your dose adjustments if possible
using the size warfarin pill the patient has

Questions to ask at each visit and to
determine reason for abnormal INR
Ø 1)

Any excessive bleeding or bruising?
Ø 2) Any missed or extra warfarin doses?
Ø 3) Any changes in medications?
Ø 4) Any changes in over the counter medications?
Ø 5) Any changes in diet?
Ø 6) Any illnesses?
Ø 7) Any upcoming dental or surgical procedures?
Ø 8) Any emergency room visits or hospitalizations?

Dosage Adjustment Algorithms
For target INR of 2.0 to 3.0, no bleeding
Ø

Ø

Ø

Ø

Ø

INR< 1.5
Increase weekly total dose 10 to 20%; consider extra dose
Next INR 4 to 8 days
INR 1.5 to 1.9
Increase weekly total dose 5 to 10%
Next INR 7 to 14 days
INR 2.0 to 3.0 (or 1.8-1.9; 3.1-3.2)
No change
No. of consecutive in-range INRs x 1 wk (max: 4 wks)
INR 3.1 to 3.9
Decrease weekly total dose 5 to 10%
Next INR 7 to 14 days
4.0 to 4.9
Hold for 0 to 1 day then decrease weekly total dose 10%
Next INR 4 to 8 days

Ebell MH. Am Fam Physician 2005;71:1979-82

Significantly Elevated INRs
INR 5-8.9 (measurable) and no significant bleeding:
Omit 1 to 2 doses
Reduce total dose 10 to 20 percent
Monitor frequently
INR= 8.0 on Coaguchek monitor in office
MEANS IS 8 OR ABOVE NOT JUST 8.
Draw Stat PT/INR and send to Jefferson Lab
Keep patient in office
Ø INR ≥ 9 (or ≥ the highest # measured at lab)
Send to ER as INR could be as high as 20 and
needs reversal
LOOK CAREFULLY AT THE INR RESULT: IF THERE IS A
GREATER THAN (>) SIGN IN FRONT OF IT, THAT
MEANS IT COULD BE UP TO AN INR OF 20.
Ø

Ebell MH. Am Fam Physician 2005;71:1979-82

Warfarin Reversal Agent
Ø Vitamin K

Indicated in patients treated with warfarin when reversal
of the anticoagulant effects is needed (e.g., due to lifethreatening or uncontrolled bleeding).
Ø Intracerebral hemorrhage:
Replace clotting factors within 90 minutes of emergency
department arrival.
PCC (Prothrombin complex concentrate) generally preferred
to fresh frozen plasma to restore clotting factors in patients
requiring urgent warfarin reversal.

Anticoagulation Module in EPIC
•Keeps track of all anticoagulation patients
•Shows patient’s warfarin regimen
•Sends a message to the INR reminder list in EPIC
so patients who fail to check their INR are
contacted.
•Prints out a warfarin calendar with the patient’s
dosing regimen and their date of their next INR.

New Anticoagulation Patient
• Under Referrals you can chose to make an Anticoagulation
Referral.
• Make sure and choose FAM 33 S 9th ST Anticoagulation
• You should also task Katie (Catherine DiSandro)
• Please let Katie know about any new patient started on
warfarin
• Include the duration of therapy if known and indication for
therapy
• The patient will need an appointment soon and Katie or
Shakia can help set this up.

Creating an Anticoagulation Episode
• Once the Anticoagulation Nurse receives an
anticoagulation referral, an Anticoagulation Episode
will be made. This Episode will continue as long as the
patient remains on anticoagulation
• Though the module was designed for warfarin it can
be used with minor modifications to remind us when
our DOAC patients need to show up – either for lab
work or to stop their anticoagulation.

Anticoagulation Module

Find the
anticoagulation
module under:
“Rarely used” then
“Quick Navigators”
and open it and star it
so it is easier to FIND.

Anticoag

In the module are
various headings
Click on these headings
to enter data:
1) Patient Findings
2) Flowsheet Data
(CHA2DS2VASc and
Has-Bled)
3) Anticoagulation
Tracking

Under Patient
Findings are
typical history
questions to ask
patients on
Anticoagulation

Anticoagulation
Tracking
In order to keep track
of patients and to give
them home warfarin
instructions, the
tracking part of the
module needs to be
filled out at every visit.

The MA needs to
enter the POC INR
where it says POCT

This will both drop an
order and enter the
result.

If the INR is done
at the same visit, it
will automatically
go to select an INR
for dosing.
Otherwise just
click on the INR
you will use.
If you are using the module
for a patient who is on a
DOAC select the No INR box.

Current
Maintenance Plan
If you need to adjust
the patient’s warfarin
regimen, click on the
current maintenance
plan which on this
one is 10 mg every
Monday and Friday
and 5 mg all the
other days.

“Edit maintenance
Plan” will pop up
1. Enter tablets patient has
on hand
2. Choose every day or
weekly
3. Enter number of each
size tablet
4. Use “Do not use
maintenance plan” for
DOACs
5. Click on today and chart
will autofill

Next pick the date for
the next INR
“Critical” will pick a couple
of days
“Fluctuating” will pick one
week
“Stable” will pick 4 weeks
Then either click on the
suggested INR date or
enter your own choice
using the calendar.

INR Reminder
Inbasket in EPIC
1) Once the INR is overdue a
message is sent to the INR
Reminder Pool inbasket in
EPIC.
2) If you do not put in the
return date for the INR, it will
go to the pool.
3) To avoid extra work for
staff and also remind patient
when their INR is due please
fill out the date of next INR.

After Visit Summary
The AVS will show:
1) Warfarin dosing including pill
size and number
2) Date for return for the next
INR.
3) This summary also
demonstrates that a boost
dose was given. You enter this
by clicking on the box on the
date in the tracer and a pop
up will appear that you can
then fill in the one day change
in dose.

If you want this information
to appear in your note chose
the
Amb J AC Physician Visit Note
If you chose this note you can still
do everything you normally do
during a regular visit. It does not
limit you or make anticoagulation
your primary problem.
The only difference is that it
brings your anticoag
documentation into your office
visit note.

Clinical Lab Recommendations Prior to and
During Oral Anticoagulant Therapy
Warfarin
DOAC
• CBC (complete blood
count) annually
• PT (prothrombin time)
see above
• INR (international
normalized ratio)see
above

• CBC annually
• Serum creatinine
annually unless have CKD
then more frequently
depending on the level of
CKD
• Liver function tests at
least annually
2020 U. S. Food & Drug administration

Warfarin: Advantages and Disadvantages
Advantages

Disadvantages

• Long track record with
predictable benefits and
results.
• Once daily dosing.
• Ability to readily measure
anticoagulant effect with
INR test.

• Narrow therapeutic window.
• Diet, disease states, and drugs may
significantly alter INR.
• INR must be monitored regularly.
• Maintaining INRs within the target
range optimizes the balance of
efficacy and safety.
• Dosing schedule can be
complicated.
• Contraindicated in pregnant
women.
2020 U.S. Food & Drug Administration

DOACS: Advantages and Disadvantages

Advantages
• No regular laboratory monitoring for
anticoagulant effect.
• Rapid onset/offset of action.
• Fewer drug interactions.
• Predictable pharmacokinetics.
• Efficacy and safety are at least as
good as warfarin (for stroke
prevention in atrial fibrillation, and
treatment and secondary prevention
of venous thromboembolism).
• Lower rates of stroke caused by
bleeding in the brain.

Disadvantages
• No widely agreed on laboratory
test to monitor anticoagulant
effect.
• Some DOACS may cause upset
stomach.
• DOACs in general have a shorter
half-life than warfarin, making
missed doses more
consequential.
• No adequate and well-controlled
studies in pregnant women.
Should only be used during
pregnancy if the potential
benefit outweighs the potential
risk to the mother and fetus.
2020 U.S. Food & Drug Administration

DOACs and Approved Indications
DOAC

Apixaban
Dabigatran

Primary VTE
Prophylaxis
in Hip/Knee
Replacement
Surgery

DVT/PE
Treatment

Secondary
Prevention
of
Recurrent
DVT/PE

X

X

X

X

X (hip)

X

X

X

X

X

X

X

Edoxaban
Rivaroxaban

NonValvular
Atrial
Fibrillation

X

X

Primary VTE
Prophylaxis of
Adult Patients
Hospitalized for
an Acute
Medical Illness

X

Reduce Risk of Major
Cardiovascular
Events in CAD and
PAD patients (in
combination with
aspirin use)

X

2020 U.S. Food & Drug Administration

Contraindications and Relative
Contraindications to DOACs
• 1) Mechanical heart valves
• 2) Antiphospholipid syndrome
• 3) Obesity/cachexia
• 4) Gastric bypass
• 5) Cost
• 6) Drug interactions
• 7) Failure of DOACs
• 8) Patient preference

DOAC Monitoring
• In addition to laboratory monitoring parameters, a comprehensive
DOAC monitoring approach should include the following items
assessed at each follow-up:
• 1. Current health status.
• 2. Adherence and cost.
• 3. Bleeding/thromboembolic events.
• 4. Adverse effects.
• 5. Complete medication review for drug interactions.
• 6. Reassessment of appropriateness of therapy.
• 7. Repeat warranted laboratory parameters.
• 8. Continuing follow-up appointments for patients.

DOAC Safety Considerations and Interaction
• Improper Use of DOACS:
Only 70% of DOAC prescriptions were appropriate.
24% of patients received an inappropriate dose. Of this 24%:
57% received a reduced dose with no clear indication.
43% received a dose that was not reduced while indicated. (Lavoie 2016)
• Dietary interactions to consider:
Dabigatran capsules must be swallowed whole and not opened due to the risk of
increased absorption.
Rivaroxaban (15 and 20 mg) should be taken with food for adequate absorption.
• Disease state interactions include:
Renal function
Renal elimination differs among DOACs
From more to less renal elimination: dabigatran > edoxaban> rivaroxaban > apixaban
2020 U.S. Food & Drug Administration

DOAC Drug Interactions
Dabigatran

Apixaban

Rivaroxaban

Edoxaban

Drug Interactions

Effect of DOAC

Recommendations

P-gp inhibitors

Increase in concentration

Reduce dose or avoid depending on renal function

P-gp inducers

Significant reduction in
concentration

Avoid use

Antacids

Moderate reduction in
concentration

No dosing adjustments required; consider spacing
regiments by 2 hours

Strong CYP3A4 inhibitor +
P-gp inhibitor

Significant increase in
concentration

Reduce dose or avoid use

Moderate CYP3A4 inhibitor + P-gp
inhibitor

Moderate increase in
concentration

No precaution necessary
Avoid use in patient with severe renal insufficiency

Strong CYP3A4 inducer or
P-gp inducer

Significant reduction in
concentration

Avoid use

Strong CYP3A4 inhibitor +
P-gp inhibitor

Significant increase in
concentration

Avoid use

Moderate CYP3A4 inhibitor + P-gp
inhibitor

Moderate increase in
concentration

No precaution necessary
Avoid use in patient with severe renal insufficiency

Strong CYP3A4 inducer or
P-gp inducer

Significant reduction in
concentration

Avoid use

P-gp inhibitor

Increase in concentration

AF: Do not reduce dose
VTE treatment: Reduce dose

P-gp inducer

Significant reduction in
concentration

Avoid use with rifampin

Chen 2020

Europace 2021

Drug examples
Strong CYP3A4 inhibitors+combined P-gp inhibitor
Moderate CYP3A4 inhibitor+combined P-gp inhibitor
Strong CYP3A4 inducer+combined P-gp inducer
Strong CYP3A4 inducers
P-gp inhibitors

P-gp inducers

Itraconazole, ketoconazole,
ritonavir
Clarithromycin, diltiazem
Carbamazepine, rifampin, St.
John’s wort
Phenytoin
Amiodarone, clarithromycin,
cyclosporine, dronedarone,
erythromycin, ivacaftor,
ketoconazole, nifedipine,
quinidine, ranolazine, ticagrelor,
tolvaptan, verapamil
Rifampin

Chen 2020

DOAC Reversal
• DOACs have relatively short half-lives. Major bleeding that
occurs in patients taking DOACs is often able to be managed by
temporarily discontinuing the anticoagulant and providing
supportive measures (compression, surgical repair, fluid and/or
blood replacement).
• Reversing anticoagulation places patients at their baseline
elevated risk of thromboembolism. Consider restarting
anticoagulation as soon as medically appropriate.
• Use of reversal agent should only be considered if the bleed is
life threatening, in a critical organ, or is not controlled with
supportive measures.

DOAC Reversal agents

• Time (12-24 hours assuming normal renal function)
• Dabigatran (Pradaxa): idarucizumab (Praxabind) is a humanized
monoclonal antibody fragment that binds to dabigatran. Wholesale
cost $3500. Approved by FDA October 2015.
• Factor Xa inhibitors (rivaroxaban (Xarleto), apixaban (Eliquis),
edoxaban (Savaysa), and enoxaparin (Lovenox)): andexanet alfa
(AndexXa) is a modified recombinant human factor Xa molecule
that binds and sequesters factor Xa inhibitors, thereby restoring
thrombin generation and normal hemostatic mechanisms.
3 or 4 factor PCC (prothrombin complex concentrate) (which
also use for immediate warfarin reversal).
• The median projected cost of Andexanet was $24750/patient,
compared to $5670/patient for PCC (P<0.001). The median hospital
reimbursement for potential Andexanet candidates was
$26050/hospitalization (71% Medicare, 29% commercial insurance)

US Cost Comparison of DOACs
Apixaban

Dabigatran

Rivaroxaban

Edoxaban

Cash price

$300–$500/mo
$8.38/tablet

$300–$500/mo
$8.01/tablet

$350–$600/mo
$8.38/tablet

$350/mo
$13.46 per tablet

Copay card*

Yes: must not have
Medicaid or Medicare

Yes: must not have
Yes: must not have
Medicaid or Medicare Medicaid or Medicare

Yes: must not have
Medicaid or Medicare

Copay

$10/mo

$5/mo

$10/mo

$4/mo

Free 30-d
coupon

yes

no

no

no

Patient
assistance
program

Bristol-Myer
Squibb

Boehringer-Ingelheim Johnson & Johnson

None available

Eligibility
for patient
assistance
program

US resident
Limited or no
prescription coverage
Income requirements

US resident
Limited or no
prescription coverage
Income requirements

N/A

US resident
Limited or no
prescription coverage
Income requirements

Chen et al

Perioperative Anticoagulation
• 1) Please make sure the patient is seen in an appointment as there are risks
of bleeding or thrombosis when you make decisions about perioperative
anticoagulation.
• 2) Determine and discuss both the risks of bleeding and the risk of
thrombosis of both the patient’s condition and the planned procedure.
• 3) If needed, discuss risks of the procedure and of bleeding and thrombosis
with the interventionalist.
• 3) Procedures such as dental procedures, cataracts, and many skin
procedures can be done on anticoagulation. If the patient is on warfarin,
make sure the INR is in the therapeutic range.
• 4) Patients with a high risk of thrombosis on warfarin may need bridging
anticoagulation. DOACs do not need bridging.
• 5) Post op decide when to restart anticoagulation depending again on risk
of bleeding and thrombosis. Warn patients of the risk of bleeding or
clotting.

MAPPP app from IPRO

Manage Anticoag App
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